The potential role of cholesterol in Parkinson’s disease neuropathology: perpetrator or victim

[1]  Ali I. Al-Gareeb,et al.  A story of the potential effect of non-steroidal anti-inflammatory drugs (NSAIDs) in Parkinson’s disease: beneficial or detrimental effects , 2023, Inflammopharmacology.

[2]  Ali I. Al-Gareeb,et al.  Pros and cons for statins use and risk of Parkinson's disease: An updated perspective , 2023, Pharmacology research & perspectives.

[3]  Yinji Liang,et al.  High-cholesterol diet promotes depression- and anxiety-like behaviors in mice by impact gut microbe and neuroinflammation. , 2023, Journal of affective disorders.

[4]  Ali I. Al-Gareeb,et al.  SIRT1 pathway in Parkinson’s disease: a faraway snapshot but so close , 2022, Inflammopharmacology.

[5]  Sharon H. Hrynkow,et al.  Intravenous 2-hydroxypropyl-β-cyclodextrin (Trappsol® Cyclo™) demonstrates biological activity and impacts cholesterol metabolism in the central nervous system and peripheral tissues in adult subjects with Niemann-Pick Disease Type C1: Results of a phase 1 trial. , 2022, Molecular genetics and metabolism.

[6]  Su Min Park,et al.  Role of reactive oxygen species in regulating 27-hydroxycholesterol-induced apoptosis of hematopoietic progenitor cells and myeloid cell lines , 2022, Cell Death & Disease.

[7]  M. Warner,et al.  Liver X Receptor Regulation of Glial Cell Functions in the CNS , 2022, Biomedicines.

[8]  R. Barker,et al.  Age-related pathological impairments in directly reprogrammed dopaminergic neurons derived from patients with idiopathic Parkinson’s disease , 2022, Stem cell reports.

[9]  Luca Tiano,et al.  Impact of dyslipidemia in the development of cardiovascular complications: Delineating the potential therapeutic role of coenzyme Q10. , 2022, Biochimie.

[10]  S. Park,et al.  Relationship between Brain Metabolic Disorders and Cognitive Impairment: LDL Receptor Defect , 2022, International journal of molecular sciences.

[11]  F. Panza,et al.  Does the imbalance in the apolipoprotein E isoforms underlie the pathophysiological process of sporadic Alzheimer's disease? , 2022, Alzheimer's & dementia : the journal of the Alzheimer's Association.

[12]  Tao Wang,et al.  High cholesterol and 27-hydroxycholesterol contribute to phosphorylation of tau protein by impairing autophagy causing learning and memory impairment in C57BL/6J mice. , 2022, The Journal of nutritional biochemistry.

[13]  Hee-Sun Kim,et al.  Anti-Inflammatory and Neuroprotective Mechanisms of GTS-21, an α7 Nicotinic Acetylcholine Receptor Agonist, in Neuroinflammation and Parkinson’s Disease Mouse Models , 2022, International journal of molecular sciences.

[14]  Dingfeng Li,et al.  Brain cell type-specific cholesterol metabolism and implications for learning and memory , 2022, Trends in Neurosciences.

[15]  Qiming Liu,et al.  Visceral adipose tissue had a causal, independent role in lowering the risk of Parkinson's disease: A mendelian randomization study. , 2021, Parkinsonism & related disorders.

[16]  Ali I. Al-Gareeb,et al.  Testosterone in COVID-19: An Adversary Bane or Comrade Boon , 2021, Frontiers in Cellular and Infection Microbiology.

[17]  Gracia-Rubio Irene,et al.  SR-B1, a Key Receptor Involved in the Progression of Cardiovascular Disease: A Perspective from Mice and Human Genetic Studies. , 2021, Biomedicines.

[18]  F. Church.  Treatment Options for Motor and Non-Motor Symptoms of Parkinson’s Disease , 2021, Biomolecules.

[19]  Maxim N. Artyomov,et al.  Selective removal of astrocytic APOE4 strongly protects against tau-mediated neurodegeneration and decreases synaptic phagocytosis by microglia , 2021, Neuron.

[20]  T. Collet,et al.  Lowering blood cholesterol does not affect neuroinflammation in experimental autoimmune encephalomyelitis , 2021, Journal of neuroinflammation.

[21]  J. Dutton,et al.  The thrombin receptor links brain derived neurotrophic factor to neuron cholesterol production, resiliency and repair after spinal cord injury , 2021, Neurobiology of Disease.

[22]  M. Banach,et al.  Effects of statins on mitochondrial pathways , 2021, Journal of Cachexia, Sarcopenia and Muscle.

[23]  C. Missale,et al.  Impaired dopamine D3 and nicotinic acetylcholine receptor membrane localization in iPSCs-derived dopaminergic neurons from two Parkinson’s disease patients carrying the LRRK2 G2019S mutation , 2020, Neurobiology of Aging.

[24]  R. Moratalla,et al.  The Role of Cholesterol in α‐Synuclein and Lewy Body Pathology in GBA1 Parkinson's Disease , 2020, Movement disorders : official journal of the Movement Disorder Society.

[25]  T. Behl,et al.  The Interplay of ABC Transporters in Aβ Translocation and Cholesterol Metabolism: Implicating Their Roles in Alzheimer’s Disease , 2020, Molecular Neurobiology.

[26]  A. Santoni,et al.  Liver X Receptors: Regulators of Cholesterol Metabolism, Inflammation, Autoimmunity, and Cancer , 2020, Frontiers in Immunology.

[27]  J. Brouwers,et al.  Explorative Combined Lipid and Transcriptomic Profiling of Substantia Nigra and Putamen in Parkinson’s Disease , 2020, Cells.

[28]  P. Martínez-Martín,et al.  The Non‐Motor Symptoms Scale in Parkinson’s disease: Validation and use , 2020, Acta neurologica Scandinavica.

[29]  Benjamin Hall,et al.  Lipid metabolism in astrocytic structure and function. , 2020, Seminars in cell & developmental biology.

[30]  Wei Song,et al.  Effects of Higher Serum Lipid Levels on the Risk of Parkinson's Disease: A Systematic Review and Meta-Analysis , 2020, Frontiers in Neurology.

[31]  P. Huang,et al.  Dilated Perivascular Space in the Midbrain May Reflect Dopamine Neuronal Degeneration in Parkinson’s Disease , 2020, Frontiers in Aging Neuroscience.

[32]  S. Chinnathambi,et al.  Role of Microglia in Regulating Cholesterol and Tau Pathology in Alzheimer’s Disease , 2020, Cellular and Molecular Neurobiology.

[33]  C. Mendivil,et al.  ApoE and apoC-III-defined HDL subtypes: a descriptive study of their lecithin cholesterol acyl transferase and cholesteryl ester transfer protein content and activity , 2020, Lipids in Health and Disease.

[34]  Junxia Xie,et al.  Potassium channels and their emerging role in parkinson's disease , 2020, Brain Research Bulletin.

[35]  Patrik Brundin,et al.  Parkinson Disease Epidemiology, Pathology, Genetics, and Pathophysiology. , 2020, Clinics in geriatric medicine.

[36]  C. Dobson,et al.  A Role of Cholesterol in Modulating the Binding of α-Synuclein to Synaptic-Like Vesicles , 2020, Frontiers in Neuroscience.

[37]  N. Chen,et al.  Endoplasmic reticulum stress, an important factor in the development of Parkinson's disease. , 2020, Toxicology letters.

[38]  A. Vercesi,et al.  Mitochondrial bioenergetics and redox dysfunctions in hypercholesterolemia and atherosclerosis. , 2019, Molecular aspects of medicine.

[39]  A. Schapira,et al.  Parkinson disease , 2019, European journal of neurology.

[40]  Kyungdo Han,et al.  Trends in the incidence and prevalence of Parkinson’s disease in Korea: a nationwide, population-based study , 2019, BMC Geriatrics.

[41]  T. Scheenen,et al.  GABAergic changes in the thalamocortical circuit in Parkinson's disease , 2019, Human brain mapping.

[42]  P. Fishman,et al.  The role of high‐intensity focused ultrasound as a symptomatic treatment for Parkinson's disease , 2019, Movement disorders : official journal of the Movement Disorder Society.

[43]  S. Ho,et al.  The interplay of aging, genetics and environmental factors in the pathogenesis of Parkinson’s disease , 2019, Translational Neurodegeneration.

[44]  E. Castrén,et al.  Cholesterol recognition motifs in the transmembrane domain of the tyrosine kinase receptor family: the case for TRKB , 2019, bioRxiv.

[45]  C. Raoul,et al.  Regulation of Brain Cholesterol: What Role Do Liver X Receptors Play in Neurodegenerative Diseases? , 2019, International journal of molecular sciences.

[46]  D. Geerts,et al.  Liver X Receptor Alpha Is Important in Maintaining Blood-Brain Barrier Function , 2019, Front. Immunol..

[47]  Weihua Li,et al.  Computational insights into the interaction mechanisms of estrogen‐related receptor alpha with endogenous ligand cholesterol , 2019, Chemical biology & drug design.

[48]  D. Raben,et al.  Lipid Metabolism Crosstalk in the Brain: Glia and Neurons , 2019, Front. Cell. Neurosci..

[49]  H. Furuya,et al.  Management of Dysphagia in Patients with Parkinson's Disease and Related Disorders , 2019, Internal medicine.

[50]  S. Bennett,et al.  Dysregulated Lipid Metabolism and Its Role in α-Synucleinopathy in Parkinson’s Disease , 2019, Front. Neurosci..

[51]  S. Ramón y. Cajal,et al.  Brain ApoA-I, ApoJ and ApoE Immunodetection in Cerebral Amyloid Angiopathy , 2019, Front. Neurol..

[52]  Silvia Maioli,et al.  Alterations in cholesterol metabolism as a risk factor for developing Alzheimer’s disease: Potential novel targets for treatment , 2019, The Journal of Steroid Biochemistry and Molecular Biology.

[53]  A. Petrov,et al.  Cholesterol and the Safety Factor for Neuromuscular Transmission , 2019, International journal of molecular sciences.

[54]  N. Rezaei,et al.  Plasma levels of brain-derived neurotrophic factor in patients with Parkinson disease: A systematic review and meta-analysis , 2019, Brain Research.

[55]  Hainan Zhang,et al.  Serum level of brain-derived neurotrophic factor in Parkinson's disease: a meta-analysis , 2019, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[56]  C. Cupidi,et al.  Brain‐derived neurotrophic factor modulates cholesterol homeostasis and Apolipoprotein E synthesis in human cell models of astrocytes and neurons , 2018, Journal of cellular physiology.

[57]  R. Dierckx,et al.  Brain-Derived Neurotrophic Factor in Brain Disorders: Focus on Neuroinflammation , 2018, Molecular Neurobiology.

[58]  K. Choi,et al.  Metabolic syndrome and risk of Parkinson disease: A nationwide cohort study , 2018, PLoS medicine.

[59]  Nir Giladi,et al.  Higher serum cholesterol and decreased Parkinson's disease risk: A statin‐free cohort study , 2018, Movement disorders : official journal of the Movement Disorder Society.

[60]  Miguel Moutinho,et al.  The mevalonate pathway in neurons: It's not just about cholesterol. , 2017, Experimental cell research.

[61]  G. Halliday,et al.  α-Synuclein Regulates Neuronal Cholesterol Efflux , 2017, Molecules.

[62]  Dr. Amarendranath Choudhury,et al.  Hypercholesterolemia causes psychomotor abnormalities in mice and alterations in cortico-striatal biogenic amine neurotransmitters: Relevance to Parkinson's disease , 2017, Neurochemistry International.

[63]  Ali I. Al-Gareeb,et al.  Acylation-stimulating protein is a surrogate biomarker for acute myocardial infarction: Role of statins , 2017, Journal of laboratory physicians.

[64]  Gokula Mohan,et al.  Neuroinflammation pathways: a general review , 2017, The International journal of neuroscience.

[65]  R. Mailman,et al.  Statins may facilitate Parkinson's disease: Insight gained from a large, national claims database , 2017, Movement disorders : official journal of the Movement Disorder Society.

[66]  B. Nordestgaard,et al.  Low LDL cholesterol, PCSK9 and HMGCR genetic variation, and risk of Alzheimer’s disease and Parkinson’s disease: Mendelian randomisation study , 2017, British Medical Journal.

[67]  K. Bendtzen,et al.  Cholesterol crystals enhance TLR2- and TLR4-mediated pro-inflammatory cytokine responses of monocytes to the proatherogenic oral bacterium Porphyromonas gingivalis , 2017, PloS one.

[68]  V. Trezza,et al.  Can Cholesterol Metabolism Modulation Affect Brain Function and Behavior? , 2017, Journal of cellular physiology.

[69]  A. Vejux,et al.  Contribution of cholesterol and oxysterols to the pathophysiology of Parkinson's disease. , 2016, Free radical biology & medicine.

[70]  Shaomin Li,et al.  The biomarkers of immune dysregulation and inflammation response in Parkinson disease , 2016, Translational Neurodegeneration.

[71]  M. Petroni,et al.  Dietary habits and neurological features of Parkinson's disease patients: Implications for practice. , 2016, Clinical nutrition.

[72]  Ahmed Negida,et al.  Coenzyme Q10 for Patients with Parkinson's Disease: A Systematic Review and Meta-Analysis. , 2016, CNS & neurological disorders drug targets.

[73]  Wei Song,et al.  The serum lipid profile of Parkinson's disease patients: a study from China , 2015, The International journal of neuroscience.

[74]  B. Vestergaard,et al.  Cholesterol facilitates interactions between α‐synuclein oligomers and charge‐neutral membranes , 2015, FEBS letters.

[75]  O. Ghribi,et al.  Does the oxysterol 27-hydroxycholesterol underlie Alzheimer's disease–Parkinson's disease overlap? , 2015, Experimental Gerontology.

[76]  J. Blesa,et al.  Oxidative stress and Parkinson’s disease , 2015, Front. Neuroanat..

[77]  I. Vattulainen,et al.  Cholesterol under oxidative stress-How lipid membranes sense oxidation as cholesterol is being replaced by oxysterols. , 2015, Free radical biology & medicine.

[78]  Hueng-Sik Choi,et al.  Estrogen‐related receptor gamma regulates dopaminergic neuronal phenotype by activating GSK3β/NFAT signaling in SH‐SY5Y cells , 2015, Journal of neurochemistry.

[79]  Xuemei Huang,et al.  Statins, plasma cholesterol, and risk of Parkinson's disease: A prospective study , 2015, Movement disorders : official journal of the Movement Disorder Society.

[80]  Juan Zhang,et al.  Cholesterol metabolism and homeostasis in the brain , 2015, Protein & Cell.

[81]  A. Tall,et al.  Cholesterol, inflammation and innate immunity , 2015, Nature Reviews Immunology.

[82]  Lina Huang,et al.  Inflammatory response in Parkinson's disease (Review). , 2014, Molecular medicine reports.

[83]  M. Sikorska,et al.  Nanomicellar formulation of coenzyme Q10 (Ubisol-Q10) effectively blocks ongoing neurodegeneration in the mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model: potential use as an adjuvant treatment in Parkinson's disease , 2014, Neurobiology of Aging.

[84]  Stephanie D. Wilson,et al.  A randomized clinical trial of high-dosage coenzyme Q10 in early Parkinson disease: no evidence of benefit. , 2014, JAMA neurology.

[85]  Wei Chen,et al.  Association of glycogen synthase kinase-3β with Parkinson’s disease (Review) , 2014, Molecular medicine reports.

[86]  I. Levitan,et al.  Cholesterol binding to ion channels , 2014, Front. Physiol..

[87]  M. Vizcaychipi,et al.  Neuroinflammation: The role and consequences , 2014, Neuroscience Research.

[88]  M. Sikorska,et al.  Orally delivered water soluble Coenzyme Q10 (Ubisol-Q10) blocks on-going neurodegeneration in rats exposed to paraquat: potential for therapeutic application in Parkinson’s disease , 2014, BMC Neuroscience.

[89]  M. Mao,et al.  The neuroprotective roles of BDNF in hypoxic ischemic brain injury. , 2013, Biomedical reports.

[90]  H. Gendelman,et al.  Sodium Phenylbutyrate Controls Neuroinflammatory and Antioxidant Activities and Protects Dopaminergic Neurons in Mouse Models of Parkinson’s Disease , 2012, PloS one.

[91]  Richard L. Doty,et al.  Olfactory dysfunction in Parkinson disease , 2012, Nature Reviews Neurology.

[92]  T. Rhen,et al.  The oxysterol 27‐hydroxycholesterol regulates α‐synuclein and tyrosine hydroxylase expression levels in human neuroblastoma cells through modulation of liver X receptors and estrogen receptors–relevance to Parkinson’s disease , 2011, Journal of neurochemistry.

[93]  O. Ghribi,et al.  Silencing GADD153/CHOP Gene Expression Protects against Alzheimer's Disease-Like Pathology Induced by 27-Hydroxycholesterol in Rabbit Hippocampus , 2011, PloS one.

[94]  M. Fivaz,et al.  Lanosterol induces mitochondrial uncoupling and protects dopaminergic neurons from cell death in a model for Parkinson's disease , 2011, Cell Death and Differentiation.

[95]  G. Bing,et al.  Lipopolysaccharide Animal Models for Parkinson's Disease , 2011, Parkinson's disease.

[96]  K. Pahan,et al.  Prospects of Statins in Parkinson Disease , 2011, The Neuroscientist : a review journal bringing neurobiology, neurology and psychiatry.

[97]  Brij B. Singh,et al.  The oxysterol 27-hydroxycholesterol increases β-amyloid and oxidative stress in retinal pigment epithelial cells , 2010, BMC Ophthalmology.

[98]  Romain Meeusen,et al.  Neuroplasticity — Exercise-Induced Response of Peripheral Brain-Derived Neurotrophic Factor , 2010, Sports medicine.

[99]  A. Teixeira,et al.  Serum levels of brain-derived neurotrophic factor correlate with motor impairment in Parkinson’s disease , 2010, Journal of Neurology.

[100]  E. Masliah,et al.  Lovastatin ameliorates α-synuclein accumulation and oxidation in transgenic mouse models of α-synucleinopathies , 2010, Experimental Neurology.

[101]  G. Barceló-Coblijn,et al.  The role of α-synuclein in brain lipid metabolism: a downstream impact on brain inflammatory response , 2009, Molecular and Cellular Biochemistry.

[102]  D. Rubinsztein,et al.  Wild-type but not mutant huntingtin modulates the transcriptional activity of liver X receptors , 2009, Journal of Medical Genetics.

[103]  F. Pfrieger,et al.  Marked differences in cholesterol synthesis between neurons and glial cells from postnatal rats , 2009, Journal of neurochemistry.

[104]  M. Beal,et al.  Mitochondrial biology and oxidative stress in Parkinson disease pathogenesis , 2008, Nature Clinical Practice Neurology.

[105]  H. Bimonte-Nelson,et al.  High cholesterol‐induced neuroinflammation and amyloid precursor protein processing correlate with loss of working memory in mice , 2008, Journal of neurochemistry.

[106]  M. Kivipelto,et al.  Total cholesterol and the risk of Parkinson disease , 2008, Neurology.

[107]  Honglei Chen,et al.  Hypertension, hypercholesterolemia, diabetes, and risk of Parkinson disease , 2007, Neurology.

[108]  Yizheng Wang,et al.  Inhibition of glycogen synthase kinase-3β protects dopaminergic neurons from MPTP toxicity , 2007, Neuropharmacology.

[109]  R. Chopra,et al.  Plasma coenzyme Q10 response to oral ingestion of coenzyme Q10 formulations. , 2007, Mitochondrion.

[110]  H. Soininen,et al.  Serum cholesterol changes after midlife and late-life cognition , 2007, Neurology.

[111]  Richard W. Murrow,et al.  Lower low‐density lipoprotein cholesterol levels are associated with Parkinson's disease , 2007, Movement disorders : official journal of the Movement Disorder Society.

[112]  K. Nave,et al.  Survival of adult neurons lacking cholesterol synthesis in vivo , 2007, BMC Neuroscience.

[113]  Albert Hofman,et al.  Serum cholesterol levels and the risk of Parkinson's disease. , 2006, American journal of epidemiology.

[114]  R. Lerner,et al.  Elevated levels of oxidized cholesterol metabolites in Lewy body disease brains accelerate α-synuclein fibrilization , 2006, Nature chemical biology.

[115]  C. Shults.  Therapeutic role of coenzyme Q(10) in Parkinson's disease. , 2005, Pharmacology & therapeutics.

[116]  Y. Moon,et al.  Mitochondrial membrane depolarization and the selective death of dopaminergic neurons by rotenone: protective effect of coenzyme Q10 , 2005, Journal of neurochemistry.

[117]  S. Przedborski.  Pathogenesis of nigral cell death in Parkinson's disease. , 2005, Parkinsonism & related disorders.

[118]  M. Sikorska,et al.  Role of mitochondria in neuronal cell death induced by oxidative stress; neuroprotection by Coenzyme Q10 , 2005, Neurobiology of Disease.

[119]  M. Leon,et al.  Cholesterol in neurologic disorders of the elderly: stroke and Alzheimer’s disease , 2004, Neurobiology of Aging.

[120]  K. Okamoto,et al.  Redox status of plasma coenzyme Q10 indicates elevated systemic oxidative stress in Parkinson's disease , 2004, Journal of the Neurological Sciences.

[121]  Z. Balázs,et al.  Uptake and transport of high‐density lipoprotein (HDL) and HDL‐associated α‐tocopherol by an in vitro blood–brain barrier model , 2004, Journal of neurochemistry.

[122]  Arto Mannermaa,et al.  Apolipoprotein E 4 Allele, Elevated Midlife Total Cholesterol Level, and High Midlife Systolic Blood Pressure Are Independent Risk Factors for Late-Life Alzheimer Disease , 2002, Annals of Internal Medicine.

[123]  Rebecca A. Betensky,et al.  α-Synuclein occurs in lipid-rich high molecular weight complexes, binds fatty acids, and shows homology to the fatty acid-binding proteins , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[124]  D. Morens,et al.  Prospective study of cigarette smoking and the risk of developing idiopathic Parkinson's disease. , 1994, American journal of epidemiology.

[125]  E. Parati,et al.  Decreased cholesterol biosynthesis in fibroblasts from patients with Parkinson disease. , 1993, Biochemical medicine and metabolic biology.

[126]  C. Teunissen,et al.  Cholesterol and markers of cholesterol turnover in multiple sclerosis: relationship with disease outcomes. , 2016, Multiple sclerosis and related disorders.

[127]  D. Perani,et al.  In vivo microglia activation in very early dementia with Lewy bodies, comparison with Parkinson's disease. , 2013, Parkinsonism & related disorders.

[128]  T. Yamanushi,et al.  Effects of squalene/squalane on dopamine levels, antioxidant enzyme activity, and fatty acid composition in the striatum of Parkinson's disease mouse model. , 2013, Journal of oleo science.

[129]  D. Bansal,et al.  Statin use and risk of Parkinson’s disease: a meta-analysis of observational studies , 2012, Journal of Neurology.

[130]  C. Tanaka,et al.  GABAA receptor but not muscarinic receptor density was decreased in the brain of patients with Parkinson's disease. , 1988, Japanese journal of pharmacology.